Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche and Genentech, and by Dr. Sonny Hsiao, UC Berkeley cell biologist and inventor of Acepodia’s core technology. Acepodia is a privately held biotechnology company focused on developing innovative, highly effective cell therapies to treat cancers.
Acepodia is developing innovative, highly effective cell therapies for cancer that are broadly accessible for patients.
Acepodia is employing a flexible therapeutic design that leverages cutting edge technologies to develop the next generation of innovative, highly effective cell therapies by supercharging select oNK cells and gamma delta (γδ) T cells to target and engage cancer cells.
Our approach is based on developing the most potent immune cell lines possible and equipping them with the optimal cellular targeting mechanisms needed to engage cancer cells with proprietary platform technologies. By arming our powerful cancer-killing cells with our tumor-targeting technology, Antibody-Cell Conjugation (ACC), Acepodia believes it can develop powerful, accessible cell therapies for patients with cancer.